Published in Gene Therapy Weekly, November 25th, 2004
Halozyme's common stock will trade under the symbol "HTI."
"We are very excited about moving to the American Stock Exchange. It is indicative of the significant progress that Halozyme has made over the past few months, including raising $13.9 million in a private placement, signing an exclusive sales and marketing agreement with Baxter Healthcare for our drug product, Enhanze SC, and filing a 510(k) application...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.